PowderMed seeks permission to test bird flu vaccine in humans
PowderMed Ltd. applied to U.K. authorities for permission to start testing a vaccine against avian influenza in humans. PowderMed Ltd., which makes genetic vaccines shot into the skin on tiny gold particles, applied to U.K. authorities for permission to start testing a vaccine against avian influenza in humans. The vaccine, which PowderMed says has shown a 100% protection response in experimental tests, will be given to adult volunteers at a research clinic in London, the Oxford- based company said in an e-mailed statement today. “This is an exciting opportunity for PowderMed to conduct the first clinical trial on a vaccine which may have a very important role in the event of a future pandemic,” the company said in the statement. Closely held PowderMed is working to develop vaccines that can be made quickly, and will be easy to administer in the event that a new flu virus emerges in humans and sweeps around the world in a lethal pandemic. The vaccines work by blasting genes through the skin into human cells, which then make immune system-stimulating proteins that prepare the body for a viral attack. (Bloomberg)
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.